Compare VRDN & BBN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | VRDN | BBN |
|---|---|---|
| Founded | 2006 | 1983 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Finance Companies |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.7B | 1.0B |
| IPO Year | 2014 | N/A |
| Metric | VRDN | BBN |
|---|---|---|
| Price | $28.67 | $15.91 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 13 | 0 |
| Target Price | ★ $40.92 | N/A |
| AVG Volume (30 Days) | ★ 1.0M | 174.0K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | ★ 6.90% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $5,706,000.00 | N/A |
| Revenue This Year | $4.67 | N/A |
| Revenue Next Year | $331.57 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $9.90 | $15.37 |
| 52 Week High | $34.29 | $17.45 |
| Indicator | VRDN | BBN |
|---|---|---|
| Relative Strength Index (RSI) | 45.38 | 25.62 |
| Support Level | $26.31 | $15.59 |
| Resistance Level | $33.71 | $15.97 |
| Average True Range (ATR) | 1.58 | 0.10 |
| MACD | 0.04 | -0.07 |
| Stochastic Oscillator | 52.01 | 4.49 |
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate includes Veligrotug (formerly known as VRDN-001) for intravenous (IV) and VRDN-003 for subcutaneous (SC) administration. Veligrotug is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of thyroid eye disease (TED).
BlackRock Taxable Municipal Bond Trust is a diversified, closed-end management investment company. Its investment objective is to seek high current income, with a secondary objective of capital appreciation.